First Trust Advisors LP Raises Stake in AMAG Pharmaceuticals, Inc. (AMAG)
First Trust Advisors LP raised its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 49.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,055 shares of the specialty pharmaceutical company’s stock after buying an additional 18,227 shares during the period. First Trust Advisors LP’s holdings in AMAG Pharmaceuticals were worth $1,241,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in AMAG. Comerica Bank raised its position in shares of AMAG Pharmaceuticals by 5.1% in the fourth quarter. Comerica Bank now owns 36,399 shares of the specialty pharmaceutical company’s stock worth $837,000 after buying an additional 1,764 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of AMAG Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 406,303 shares of the specialty pharmaceutical company’s stock worth $14,140,000 after buying an additional 6,507 shares in the last quarter. Martingale Asset Management L P acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter worth $481,000. Federated Investors Inc. PA acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter worth $1,838,000. Finally, Pacad Investment Ltd. acquired a new position in shares of AMAG Pharmaceuticals during the fourth quarter worth $425,000.
Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at 18.35 on Friday. The firm’s market cap is $643.08 million. The firm has a 50-day moving average price of $18.26 and a 200 day moving average price of $23.88. AMAG Pharmaceuticals, Inc. has a 12-month low of $16.00 and a 12-month high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The firm had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. During the same quarter last year, the business posted ($0.22) earnings per share. The firm’s revenue for the quarter was up 27.6% compared to the same quarter last year. On average, equities research analysts anticipate that AMAG Pharmaceuticals, Inc. will post $5.09 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on AMAG shares. Cantor Fitzgerald set a $24.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, February 27th. Jefferies Group LLC set a $40.00 target price on AMAG Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, March 18th. Barclays PLC reissued a “hold” rating and issued a $25.00 target price on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. TheStreet lowered AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Finally, ValuEngine lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. AMAG Pharmaceuticals currently has an average rating of “Hold” and an average price target of $29.44.
In other news, SVP Julie Krop sold 1,891 shares of AMAG Pharmaceuticals stock in a transaction on Monday, May 1st. The stock was sold at an average price of $24.45, for a total transaction of $46,234.95. Following the transaction, the senior vice president now directly owns 36,777 shares in the company, valued at approximately $899,197.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.80% of the stock is currently owned by company insiders.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.